Our Story
Built for Neurological Clinical Research, Grounded in Science
At Neuroscios, we were founded on the belief that clinical trials in neurology require a different kind of partner – one with scientific depth, therapeutic focus, and operational control. Since 2013, we’ve been helping sponsors navigate the complexity of neurological clinical trials with precision and purpose.
Neuroscios was established in Graz, Austria, by Dr. Nikola Helmberg and Dr. Manfred Windisch – both with long-standing careers in neuroscience and clinical research. From the beginning, the company brought together a multidisciplinary team of scientists, physicians, psychologists, and regulatory experts with one goal: to support sponsors in bringing effective therapies for neurological disorders to patients faster.
Over the past decade, we’ve delivered more than 30 clinical studies across Alzheimer’s disease, Parkinson’s disease, stroke, and rare CNS conditions – supporting both biotech and pharma sponsors through every development phase. Our reputation is built on scientific rigor, collaborative delivery, and real-world outcomes.
Becoming Part of Sanos
In 2024, Neuroscios became part of Sanos – a global multi-niche CRO. While our leadership, scientific direction, and independence remain intact, we now benefit from broader in-house capabilities that support faster and more scalable trial delivery.
Through Sanos, we gain access to integrated clinical functions including dedicated clinical research sites, clinical trial supply, patient recruitment, and eCOA – enhancing our ability to deliver high-quality clinical trials in neurology from start to finish.
Connected to a Broader CRO Ecosystem
As part of Sanos, we operate within a full-service clinical research platform that supports trial efficiency, scientific integrity, and quality data.
Our leadership and scientific teams bring deep expertise in neurological trial execution and endpoint strategy.
Including Alzheimer’s, Parkinson’s, ALS, MS, stroke, and other neurological disorders.
Supporting translational development with biomarker integration and regulatory planning.
